The influence of proton pump inhibitor therapy on the clinical course of COVID-19
- Conditions
- SARS-CoV2J12.8J80.0Other viral pneumonia
- Registration Number
- DRKS00021523
- Lead Sponsor
- niversitätsklinikum Freiburg, Klinik für Innere Medizin II
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
Confirmed SARS-CoV2- infection, hospitalized patients
Exclusion Criteria
SARS-CoV2 infection excluded, outpatient treatment
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Prevalence of bacterial superinfection in patienst with and without proton pump inhibitor (PPI) treatment. <br>2. Development of ARDS in patients with and without PPI treatment.
- Secondary Outcome Measures
Name Time Method 1. Index mortality<br>2. Prevalence of intensive care treatment in patients with and without PPI treatment<br>3. Cours eof inflammatory markers in patients with and without PPI treatment and its impact on the development of disease associated complications
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link PPI therapy to improved outcomes in SARS-CoV-2 patients?
How does PPI therapy compare to standard-of-care treatments for viral pneumonia in clinical efficacy?
Which biomarkers correlate with PPI response in patients with J12.8/J80.0 pneumonia subtypes?
What are the potential adverse events of long-term PPI use in SARS-CoV-2 treatment regimens?
Are there synergistic effects when combining PPIs with antiviral agents like remdesivir in respiratory viral infections?